Drugs / Doxercalciferol
Doxercalciferol
also known as
Hectorol · 1 alpha D2 · 1-.alpha.-hydroxyergocalciferol · 1-hydroxyergocalciferol · 1.alpha.-hydroxyvitamin d2 · 1alpha OH vitamin D2 · GZ427397 · Hectorol (the other name for Doxercalciferol) · +1 more
Small molecule targets VDR via activation
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | HECTOROL | — | 2004-04-23 – 2025-06-11 | fda.gov ↗ |
| Approved | US (FDA) | HECTOROL | — | 1999-06-09 | fda.gov ↗ |
Trials 17 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00792857 Comparator | Nov 2008 → Sep 2009 | chronic renal failure syndrome, secondary hyperparathyroidism of renal origin | OPKO IP Holdings II, Inc. | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT01181531 Comparator | Oct 2010 → Jul 2012 | secondary hyperparathyroidism | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00502268 Comparator | Feb 2008 → Feb 2009 | calcinosis, end stage renal failure, secondary hyperparathyroidism | Southeast Renal Research Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT00257920 Comparator | Jun 2006 → Jan 2008 | end stage renal failure, secondary hyperparathyroidism of renal origin | Abbott | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | doxercalciferol | “Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT)” NCT01181531 ↗ |
| Known as | 1 alpha D2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00560300 ↗ |
| Known as | 1-.alpha.-hydroxyergocalciferol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200810 ↗ |
| Known as | 1-hydroxyergocalciferol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200810 ↗ |
| Known as | 1.alpha.-hydroxyvitamin d2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200810 ↗ |
| Known as | 1alpha OH vitamin D2 | “Patients randomized to group 1 will have the administration of 1alpha OH vitamin D2 (Hectorol) targeted to achieve serum PTH levels between 150-300 ng/ml using a Bayer Centaur...” NCT00502268 ↗ |
| Known as | GZ427397 | “Drug: Doxercalciferol (GZ427397)” NCT02859896 ↗ |
| Known as | Hectorol | “The purpose of this study is to demonstrate the safety and effectiveness of Hectorol® (doxercalciferol) capsules in treating patients with Stage 3 or Stage 4 chronic kidney...” NCT00123461 ↗6“Patients randomized to group 1 will have the administration of 1alpha OH vitamin D2 (Hectorol) targeted to achieve serum PTH levels between 150-300 ng/ml using a Bayer Centaur...” NCT00502268 ↗ “Hectorol (doxercalciferol injection)” NCT00454350 ↗ “Hectorol® (doxercalciferol capsules)” NCT00418600 ↗ “doxercalciferol capsules, Hectorol®” NCT07660536 ↗ “Hectorol (doxercalciferol capsules)” NCT00463021 ↗ |
| Known as | Hectorol (the other name for Doxercalciferol) | “Hectorol (the other name for Doxercalciferol)” NCT00889629 ↗ |
| Known as | TSA-840 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200810 ↗ |
| Action | Activate | “Vitamin D receptor agonist” CHEMBL1200810 ↗ |
| Modality | Small molecule | — CHEMBL1200810 ↗ |
| Route | Intravenous | “Vitamin D administered IV” NCT00135304 ↗ |
| Target | VDR | “Vitamin D receptor agonist” CHEMBL1200810 ↗ |